20 articles
Natural flavonoid fisetin activates mitophagy and xenophagy pathways to restrict intracellular Salmonella growth in immune cells.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions — from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
New research identifies Lp-PLA2 enzyme as therapeutic target for deadly lung disease affecting millions of workers worldwide.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
Researchers uncover how the STING immune pathway triggers mitochondrial fragmentation and DNA release, fueling deadly lung inflammation in sepsis.
Small study explores how tofacitinib may address chronic pain that persists even when inflammation is controlled in RA patients.
Clinical trial results for oral icotrokinra in treating plaque psoriasis across adult and adolescent patients published in NEJM.
FIRST-RA study follows 300 patients to measure early pain relief and functional improvements with filgotinib treatment.
Icotrokinra, a breakthrough oral peptide targeting IL-23, demonstrates significant skin clearance in psoriasis with sustained benefits through 52 weeks.
Scientists discover how blocking CD40-CD40L pathway reduces dangerous clotting in antiphospholipid syndrome patients.
A new review reveals how cellular crosstalk, non-coding RNAs, and lung microbiota drive pulmonary fibrosis — and where treatments may break through.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
Dying cancer cells release GPX4 protein that prevents immune system activation, revealing new immunotherapy targets.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
